Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04029116 · ClinicalTrials.gov registry record · Phase 3
Phase 3 Study of Oral Ibrexafungerp (SCY-078) Vs. Placebo in Subjects With Recurrent Vulvovaginal Candidiasis (VVC)
A Phase 3 study, sponsored by Scynexis.
- Completed
- Registry status
- Phase 3
- Development phase
- 440
- Enrollment target
NCT04029116: Completed Phase 3 study, sponsored by Scynexis.
NCT04029116 is a Phase 3 study that has completed, run by Scynexis. The registered enrollment target is 440 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (43% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04029116, a Phase 3 study, has completed, sponsored by Scynexis.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 440 participants
- Enrollment target
Study Summary
This study is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of oral ibrexafungerp (formerly "SCY-078") compared to placebo in female subjects 12 years and older with recurrent VVC (RVVC).
Primary Outcome
Efficacy as measured by the percentage of subjects with documented Clinical Success.
Interventions
- DRUG Placebo oral tablet
- DRUG Fluconazole Tablet
- DRUG IBREXAFUNGERP
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 440 participants |
| Start Date | 2019-10-21 |
| Est. Completion | 2021-11-29 |
| Phase | Phase 3 |
What the finished NCT04029116 record still lists
NCT04029116 is an interventional study that assigns participants to a tested intervention. The registered 440 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (43% lower).
The record links to 0 conditions, and to 3 interventions - of which Placebo oral tablet is the first listed.
NCT04029116 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04029116 about?
NCT04029116 is a clinical study titled "Phase 3 Study of Oral Ibrexafungerp (SCY-078) Vs. Placebo in Subjects With Recurrent Vulvovaginal Candidiasis (VVC)". This study is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of oral ibrexafungerp (formerly "SCY-078") compared to placebo in female subjects 12 years and older with recurrent VVC (RVVC).
What is the current status of trial NCT04029116?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 440 participants. The study started on 2019-10-21. Estimated completion is 2021-11-29.
What interventions are being tested in trial NCT04029116?
The interventions under investigation include: Placebo oral tablet (DRUG), Fluconazole Tablet (DRUG), IBREXAFUNGERP (DRUG).
Who is sponsoring clinical trial NCT04029116?
This trial is sponsored by Scynexis, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04029116's enrollment target sits among peer trials
440 867th of 2000 higher than 1,129 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05114538 · 440 participants · NA
Improving the Part C Early Intervention Service Delivery System for Children with ASD
- NCT05117619 · 440 participants · NA
The HOME Program for Individuals With Traumatic Brain Injury and Family Members
- NCT05602194 · 440 participants · Phase 3
Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma
- NCT05624879 · 440 participants · NA
Accelerated Resolution Therapy for Early Maladaptive Grief
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI